• Invest
    Investment Suite
    Stocks
    Mutual Funds
    Future and Options
    IPO
    Exchange Traded Funds
    Commodity
    Stockcase (Stock Baskets)
    Currency
    Non Convertible Debentures
    Sovereign Gold Bond
    Exclusive
    NRI Account
    Private Client Group
    Features
    SipIt
    MTF
    Investment Suite
    Exclusive
    Features
  • Platform
    Product Suite
    Kotak Neo App & Web
    Nest Trading Terminal
    NEO Trade APIs
    Features and Tools
    MTF
    Securities Accepted as Collateral
    Margin Requirements
    Equity Screeners
    Payoff Analyzer
    Calculators
    SIP Calculator
    Lumpsum Calculator
    Brokerage Calculator
    Margin Calculator
    MTF Calculator
    SWP Calculator
    CAGR Calculator
    Simple Interest Calculator
    ELSS Calculator
    Step up SIP Calculator
    All Calculators
    Product Suite
    Features and Tools
    Calculators
  • Pricing
  • Research
    Research Calls
    Long Term calls
    Short Term calls
    Intraday calls
    Derivatives calls
    Pick of the week
    Top Monthly Picks
    Research Reports
    Fundamental Research Report
    Technical Research Report
    Derivative Research Report
    Research Calls
    Research Reports
  • Market
    Stocks
    Market Movers
    Large Cap
    Mid Cap
    Small Cap
    Indices
    Nifty 50
    Bank Nifty
    FinNifty
    Nifty Midcap India
    VIX
    All Indian Indices
    Mutual Funds
    SBI Mutual Funds
    HDFC Mutual Funds
    Axis Mutual Funds
    ICICI Prudential Mutual Funds
    Nippon India Mutual Funds
    All AMC's
    IPO
    Upcoming IPO
    Current IPO
    Closed IPO
    Recently Listed IPO
    Stocks
    Indices
    Mutual Funds
    IPO
  • Learn
    Resource
    Market Ready
    Kotak Insights
    Infographic
    Podcast
    Webinars
    Youtube Channel
    Quarterly Results
    Investing Guide
    Demat Account
    Trading Account
    Share Market
    Intraday Trading
    IPO
    Mutual Funds
    Commodities
    Currency
    Futures & Options
    Derivatives
    Margin Trading
    Events
    Budget 2024
    Muhurat Trading
    Share Market Holiday
    Market Outlook 2025
    Resource
    Investing Guide
    Events
  • Partner
    Business Associates
    Fund Expert
    Kotak Connect Plus
    Startup connect
  • Support
    FAQs
    Circulars
    Bulletins
    Contact Us
    Forms Download
    Get your Statement

₹ 14112 / 14 shares

IPO Details

RHP/DRHP

Issue Date

03 Jul - 5 Jul'24

Investment/lot

₹ 14112

Price Range

960 - 1008

Lot Size

14

IPO Size

₹ 1953.01 Cr

IPO Listing Details

Listing On

10 Jul'24

Issue Price

1008

Listed Price

₹ 1325.05

Retail Gain/Listing Gain

31.45%

Start date

End date

Allotment of bids

Refund Initiation

Listing on exchange

WATCH AND LEARN
All you need to know about Emcure Pharma Limited IPO
Tune in to know more about the company, IPO issue details, product/service portfolio, and much more with Kinjal Parekh!

Emcure Pharmaceuticals is an Indian pharmaceutical company that develops, manufactures and globally markets a broad range of pharmaceutical products across several major therapeutic areas.

It is a research and development (R&D) driven company with a differentiated product portfolio that includes orals, injectables and biotherapeutics, which enables them to reach a range of target markets across over 70 countries, with a strong presence in India, Europe and Canada.

With that, let's take a look at the competitive strengths and risk factors for Emcure Pharmaceuticals Limited:

Well-placed to leverage their position in the domestic market

The company is focused on the domestic market, with sales in India contributing 48.28% of their total revenue for FY24. Since shifting their focus to Indian domestic branded generics in 1995, they have grown significantly. They are now the 13th largest pharmaceutical company in India by Domestic Sales for MAT FY24, the 4th largest by market share in their covered markets, and the largest in the gynecology and HIV antivirals therapeutic areas in India (Source: CRISIL Report).

Demonstrated capabilities of building brands

They have demonstrated strong capabilities and a proven track record in building brands. Six of their brands were ranked among the 300 highest-selling brands in the IPM in terms of Domestic Sales for MAT Financial Year 2024 (Source: CRISIL Report). Additionally, 16 of their top 20 brands were each ranked among the three highest-selling brands in their respective therapeutic areas in the IPM for the same period (Source: CRISIL Report).

Large, diversified and fast-growing product portfolio in international markets

They sell their portfolio of products in over 70 countries, with Europe and Canada being their primary international markets. Sales outside India contributed 51.72% of their total revenue for the FY24.

  • Any manufacturing or quality control problems may damage the company’s reputation and subject them to regulatory action, which could adversely affect the business.

  • Failure to comply with applicable quality standards may result in product liability claims, which could adversely affect the business, financial condition, cash flows and results of operations.

  • Any disruptions to the supply, or an increase in the pricing of raw materials and finished products that are outsourced, may adversely affect the business, cash flows, financial condition and results of operations.

Key Strategies

  • Increase market share in the domestic market.

  • Continue to invest in R&D and manufacturing capabilities to enhance and grow their differentiated product portfolio.

  • Pursue strategic acquisitions, partnerships and in-licensing arrangements.

Here are the key financials for Emcure Pharmaceuticals Limited:

Particulars (in Rs. million)

Particulars (in Rs. million)

WHAT ARE YOU LOOKING FOR?
Applying for an IPO for the first time?
Here's a video playlist to help you invest in the upcoming Indegene Limited IPO
How to apply for IPO through ASBA

How to apply for IPO through ASBA

Kotak Securities

04m 01s

Opening of account will not guarantee allotment of shares in IPO. Investors are requested to do their own due diligence before investing in any IPO.

Here are the steps to apply for Emcure Pharmaceuticals Ltd IPO:

Step 1: Log in to your Kotak Securities Demat account Log in to your Demat account to access IPO investments. Next, select the current IPO section.

Step 2: Specify IPO details Enter the number of lots and the price you wish to apply for.

Step 3: Enter UPI ID After entering your UPI ID, click submit. This will place your bid with the exchange.

Step 4: Mandate Notification Your UPI app will receive a mandate notification to block funds.

Step 5: Approve Request Your funds will be blocked once you approve the mandate request on your UPI.

Emcure Pharma IPO FAQs

Emcure Pharma IPO will list on 2024-07-10.

1953.01 is the issue size of Emcure Pharma IPO.

The minimum lot size is 14 shares and the investment required is ₹14112.

The price band of Emcure Pharma IPO is ₹960 to ₹1008.

You can read more about Emcure Pharma and its IPO from the company’s red herring prospectus (RHP) here.

The Emcure Pharmaceuticals Limited IPO has an issue size of Rs. 1,952 crores. The IPO opens for subscription on 3rd July 2024 and closes on 5th July 2024

Link Intime India Private Limited is the registrar for this IPO.

Open Demat Account to Invest in any IPO
+91 -

personImage
Open Demat Account to Invest in any IPO
+91 -

N
N
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]